12 week campaign
77% increase in organic impressions
18% download rate
10% increase website visits
Biotech companies work hard to bring innovative treatments to market. But these are complex products that continually raise challenges from growth planning to materials, process, manufacturing, regulatory compliance, and supply chain resilience, at each step of the way from clinical to commercial. As startups or isolated research teams with educational facilities they are unsure of where to turn when obstacles arise and they need help.
Our aim: for those anxious to make their clinical trials a success, we would let them tap into the insights of an industry leader. We created a whitepaper that provides a concrete action plan to scale a clinical trial into a commercial reality to position Cell Therapies as a partner who can help cell and gene therapy developers navigate these challenges at every step.
A mix of owned content and relevant curated articles helped maintain positive engagement organically and drive the key messages of the campaign.
The campaign included organic social and paid advertising targeted at commercial roles within the biotech sector across the United States and Canada and also tapped into attendees at the BioProcess conference.
A next-gen marketing strategy for a next-gen cell and gene therapy manufacturer. Cell Therapies is an industry-leading facility that manufactures and deploys cell and gene …
Showcasing the real world outcomes of new world shipping. Cloud Global are a supply chain management business with a difference. In a traditional industry Cloud …
Helping a GPS company locate their brand’s true position Austracker is an Australian GPS tracking company supplying GPS fleet tracking for transport and logistics companies, …
Giving a breath of fresh air to a 40 year old HVAC company AC Goulding are one of the smartest HVAC service providers in the …
A breakthrough brand for the brightest minds in cybersecurity. Pure Security faced a common challenge for businesses that merge. Recently formed from 4 individual businesses, …
